Clinical Trials
179 trialsA Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
FOCUS
Ohio State University Comprehensive Cancer Center
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines, Inc.
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Adaptive Symptom Self-Management Immunotherapy Study
University of Arizona
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Agni-01
Obsidian Therapeutics, Inc.
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Pfizer
Dabrafenib and/or Trametinib Rollover Study
Novartis
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
DOPACER
Institut Cancerologie de l'Ouest
GAPIMET
University of Zurich
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Pfizer
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
ADVICE
Filamon LTD
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Fred Hutchinson Cancer Center
PNeoVCA
Mayo Clinic
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
University of California, Davis
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
The Florida ASCENT Study
University of Florida
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
EBNK-ST-001
Essen Biotech
Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)
M.D. Anderson Cancer Center
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
ACT
AgonOx, Inc.
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
VSV-02 Compassionate Use in Advanced Solid Tumors
The First Affiliated Hospital of Xinxiang Medical College
DETERMINE
Cancer Research UK
EDDIS-a1
Petrov, Andrey
PAVO
Tempus AI